

1 **Title page**

2 **Article category:** Short communication

3 **Recommended manuscript title**

4 Immunogenicity and Safety of Booster Dose of S-268019-b or Tozinameran in
5 Japanese Participants: An Interim Report of Phase 2/3, Randomized, Observer-
6 Blinded, Noninferiority Study

7
8 **Authors**

9 Masaharu Shinkai,¹ Takuhiro Sonoyama,² Akari Kamitani,² Risa Shibata,² Naomi
10 Seki,³ Shinya Omoto,³ Masahiro Shinoda,¹ Takashi Sato,¹ Naoki Ishii,⁴ Kenji
11 Igarashi,² Mari Ariyasu²

12
13 ¹Department of Respiratory Medicine, Tokyo Shinagawa Hospital, 6-3-22 Higashioi,
14 Shinagawa-ku, Tokyo 140-8522, Japan

15 ²Shionogi & Co., Ltd., Drug Development and Regulatory Science Division 8F,
16 Nissay Yodoyabashi East Bldg., 3-3-13, Imabashi, Chuo-ku, Osaka 541-0042, Japan

17 ³Shionogi & Co., Ltd., Pharmaceutical Research Division 1-1, Futaba-cho 3-chome,
18 Toyonaka, Osaka 561-0825, Japan

19 ⁴Department of Gastroenterology, Tokyo Shinagawa Hospital, 6-3-22 Higashioi,
20 Shinagawa-ku, Tokyo 140-8522, Japan

21
22 **Corresponding author:** Mari Ariyasu

23 8F, Nissay Yodoyabashi East Bldg., 3-3-13, Imabashi, Chuo-ku, Osaka 541-0042,
24 Japan

25 Phone: +81-6-6209-6962

26 Fax: +81-6-6209-8047

27 Email: mari.tatsuno@shionogi.co.jp

28
29 Word count: 1990/2000

30 References: 19/20

31 Abstract word count: 150/150

32 Tables and multipanel figures: 4/4

33 Supplementary material: Appendix document, 5 tables, and 2 figures

34

35 **Abstract**

36 In this randomized, observer-blinded, phase 2/3 study, S-268019-b (n=101), a
37 recombinant spike protein vaccine, was analyzed for noninferiority versus
38 tozinameran (n=103), when given as a booster ≥ 6 months after 2-dose tozinameran
39 regimen in Japanese adults without prior COVID-19 infection. Interim results showed
40 noninferiority of S-268019-b versus tozinameran in co-primary endpoints for
41 neutralizing antibodies on day 29: geometric mean titer (GMT) (124.97 versus
42 109.70; adjusted-GMT ratio [95% CI], 1.14 [0.94-1.39]; noninferiority *P*-value,
43 <0.0001) and seroresponse rate (both 100%; noninferiority *P*-value, 0.0004). Both
44 vaccines elicited anti-spike-protein immunoglobulin G antibodies, and produced T-
45 cell response (n=29/group) and neutralizing antibodies against Delta and Omicron
46 pseudovirus and live virus variants (n=24/group) in subgroups. Most participants
47 reported low-grade reactogenicity on days 1-2, the most frequent being fatigue,
48 fever, myalgia, and injection-site pain. No serious adverse events were reported. In
49 conclusion, S-268019-b was safe and showed robust immunogenicity as a booster,
50 supporting its use as COVID-19 booster vaccine.

51

52 **JRCT ID:** jRCT2031210470

53

54 **Keywords:** booster, clinical trial, neutralization test, SARS-CoV-2, recombinant
55 spike protein, immunization

56 **Highlights**

- 57 • Third COVID-19 vaccine dose (booster) enhances immune response
- 58 • Interim phase 2/3 data for booster ≥ 6 months after the 2nd dose in Japan are
- 59 shown
- 60 • S-268019-b was noninferior to tozinameran in inducing neutralizing antibodies
- 61 • Sera boosted with either vaccines neutralized Delta and Omicron virus variants
- 62 • S-268019-b was safe, and results support its use as a booster in vaccinated
- 63 adults

64 **Introduction**

65 Cases of coronavirus disease 2019 (COVID-19) caused by severe acute
66 respiratory syndrome coronavirus 2 (SARS-CoV-2) are increasing periodically
67 because of several reasons. A third vaccine dose (booster) is recommended
68 because of concerns regarding waning humoral immunity over 6 months after the
69 second dose [1] and consequent reduced effectiveness against SARS-CoV-2
70 infection [2], as well as threats from new mutant strains that may escape the
71 vaccine-mediated immunity. Booster immunization can substantially improve the
72 humoral immune response against the emerging variants, including Omicron [3], [4].

73 S-268019-b is a novel vaccine candidate comprising a modified recombinant
74 spike protein of SARS-CoV-2 (S-910823, antigen) produced using the baculovirus
75 expression system in insect cells and a squalene-based adjuvant (A-910823). In a
76 double-blinded, phase 1/2 trial, S-268019-b showed tolerability and a robust
77 immunogenicity after two doses [5]. Here, we present the interim results of a phase
78 2/3, randomized trial in Japan, wherein the immunogenicity and safety of a single
79 booster dose of S-268019-b or tozinameran were assessed.

80

81 **Methods**

82 *Study design and participants*

83 This phase 2/3, single-center, randomized, observer-blinded, active-
84 controlled, noninferiority trial comprised three periods: screening (day -28 to -1),
85 evaluation (day 1 to 29), and follow-up (day 30 to 365) (**Figure 1**).

86 Participants were healthy immunocompetent Japanese adults (aged ≥ 20 years)
87 who had received two doses of tozinameran (BNT162b2; *Pfizer/BioNTech* mRNA
88 vaccine), with the second dose received ≥ 6 months ago. Individuals with laboratory-
89 confirmed SARS-CoV-2 infection at screening or known history of SARS-CoV-2
90 infection were excluded (See **Supplementary Methods** for details).

91 Eligible participants were randomized 1:1, stratified by age (<40 and ≥ 40
92 years) and sex, to receive an intramuscular injection of either 0.5 mL of S-268019-b
93 (10 μg antigen prepared with 50% v/v oil-in-water adjuvant emulsion) or 0.3 mL of
94 tozinameran (30 μg in saline) on day 1.

95 The study (jRCT2031210470) was conducted in compliance with the protocol,
96 the Declaration of Helsinki and Council for International Organizations of Medical
97 Sciences International Ethical Guidelines, the International Council for

98 Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Good
99 Clinical Practice Guidelines, other applicable laws and regulations, and was
100 approved by Institutional Review Board of Tokyo Shinagawa Hospital Medical
101 Corporation Association Tokyokyojuno-kai. All participants gave their written
102 informed consent.

103

104 *Outcomes*

105 The primary objective of the study was to assess the noninferiority of
106 S-268019-b versus tozinameran as a booster dose in inducing SARS-CoV-2
107 neutralizing antibodies against the live wildtype virus strain (WK-521) on day 29. The
108 co-primary endpoints included day 29 geometric mean titer (GMT) and seroresponse
109 rate (SRR) for SARS-CoV-2 neutralizing antibodies. SRR was defined as the
110 proportion of participants with a post-vaccination antibody titer ≥ 4 -fold higher than
111 the baseline.

112 Secondary endpoints comprised other immunogenicity parameters and safety.
113 These included GMT, geometric mean fold rise (GMFR), and SRR for neutralizing
114 antibodies and anti-spike protein immunoglobulin G (IgG) antibodies on days 15 and
115 29. Exploratory analyses in a smaller representative sample included neutralizing
116 antibodies against SARS-CoV-2 pseudovirus variants (D614G, Delta, and Omicron)
117 and live virus variants (wildtype, Delta, and Omicron) on day 29 and T-cell response
118 on day 15. Safety endpoints included incidence of adverse events (AEs), serious
119 AEs, AEs of special interest, treatment-related AEs (TRAEs), medically attended
120 TRAEs, solicited TRAEs, and changes in laboratory test values. Immunogenicity
121 variables with titer values below the lower limit of quantification (LLOQ) were
122 replaced with $0.5 \times$ LLOQ.

123

124 *Statistical analyses*

125 The study used a noninferiority design. Noninferiority of S-268019-b to
126 tozinameran is confirmed when the lower limit of 95% CI is >0.67 for GMT ratio
127 (S-268019-b/tozinameran) derived from the analysis of covariate model with age and
128 sex as covariates, and more than -10% for SRR difference (S-268019-b minus
129 tozinameran) by the Farrington-Manning method for neutralizing antibodies on day
130 29 [6]. The immunogenicity subset included participants who received ≥ 1 dose of the
131 study intervention, had ≥ 1 post-vaccination immunogenicity data, and were negative

132 for anti-SARS-CoV-2 N-protein antibody at screening. The safety analysis subset
133 included participants who received ≥ 1 dose of the study intervention. All analyses
134 were conducted based on the actual intervention administered.

135 Data were summarized using measures of central tendency, dispersion, and
136 frequency distribution. Unless otherwise noted, all statistical tests were performed at
137 the two-sided $\alpha=0.05$. Missing values were not imputed. All analyses were
138 performed using SAS[®] v9.4 (SAS Institute, NC, USA). (See **Supplementary**
139 **Appendix** for detailed methods and statistical analyses).

140

141 **Results**

142 *Trial Participants*

143 All 206 participants screened were enrolled in the study during December 3–
144 22, 2021. Of these, two participants with unclear randomization code were excluded
145 from the outcome analysis and 204 were analyzed (S-268019-b, n=101;
146 tozinameran, n=103) (**Supplementary Figure 1**). Baseline demographics and
147 participant characteristics were balanced across S-268019-b and tozinameran
148 groups: median age (range) was 30.0 (21-59) and 31.5 (21-60) years; male
149 population, 70% and 71%, respectively (**Supplementary Table 1**).

150

151 *Immunogenicity*

152 GMTs (95% CIs) for neutralizing antibodies at baseline were 5.47 (4.81-6.21)
153 for S-268019-b group and 6.65 (5.73-7.72) for tozinameran, which increased to
154 124.97 (108.33-144.18) and 109.70 (95.73-125.70), respectively, on day 29
155 (adjusted-GMTR 1.14; 95% CI 0.94-1.39; noninferiority *P*-value, <0.0001). The SRR
156 was 100% for both groups (SRR difference 0.0; 95% CI –5.9 to 5.9; noninferiority *P*-
157 *value*, 0.0004) (**Figure 2A and Table 1**). Thus, both co-primary endpoints were met:
158 as a booster, S-268019-b was noninferior to tozinameran in SARS-CoV-2
159 neutralization. The GMTs (95% CIs) for anti-spike protein IgG antibodies at baseline
160 were 1453.4 (1259.1-1677.8) for S-268019-b and 1808.2 (1546.8-2113.7) for
161 tozinameran; these were elevated to 48464.8 (41429.9-56694.2) and 55214.8
162 (49013.5-62200.7), respectively, on day 29 (**Figure 2B**), with both groups showing
163 100% SRR (**Supplementary Table 2**). The GMFR and GMT results were consistent
164 (**Supplementary Table 2 and Figure 2**).

165 Furthermore, neutralizing antibodies against SARS-CoV-2 pseudovirus and
166 live virus variants on day 29 were assessed in a representative sample selected from
167 the immunogenicity subset (n=24/group) (**Supplementary Table 3**). Serum samples
168 from both vaccine groups neutralized Delta and Omicron pseudovirus and live virus
169 variants with similar potency; however, GMT against live Omicron was 4-fold lower
170 versus wildtype (**Figure 2C and 2D**). T-cell responses were assessed for a subgroup
171 (n=29/group) sampled from participants who gave consent for cellular immunity
172 assessments. Both vaccines induced antigen-specific polyfunctional CD4⁺ T-cell
173 responses, as reflected in the interferon-gamma and interleukin-2 expression on day
174 15 (**Supplementary Figure 2**). A strong bias toward the T-helper type 1 phenotype
175 was noted.

176

177 *Safety*

178 Both, S-268019-b and tozinameran, displayed an acceptable safety profile as
179 a booster. There were no treatment-emergent serious AEs, deaths, grade 4-5
180 solicited TRAEs, or AEs of special interest reported until data cutoff date (February
181 4, 2022) (**Supplementary Table 4**). Overall, 96.0% (97/101) participants reported
182 364 TRAEs in the S-268019-b group, and 98.1% (101/103) participants reported 466
183 TRAEs in the tozinameran group. Furthermore, solicited systemic TRAEs were
184 reported by 69.3% (70/101) and 79.6% (82/103) participants and solicited local
185 TRAEs by 67.3% (68/101) and 72.8% (75/103) participants in the S-268019-b and
186 tozinameran groups, respectively. The most frequently reported solicited TRAEs
187 within 7 days in both booster groups were injection-site pain, fatigue, fever, myalgia,
188 and headache (**Table 2**). Most of the solicited TRAEs were grade 1-2 and were
189 reported on day 1-2 of the booster dose injection (**Supplementary Table 5**). One
190 participant in the S-268019-b group and four participants in the tozinameran group
191 experienced grade 3 solicited TRAEs.

192

193 **Discussion**

194 This study showed that S-268019-b as a booster (third) dose was noninferior
195 to tozinameran in inducing SARS-CoV-2 neutralizing antibodies. Both vaccines
196 induced neutralizing antibodies against pseudovirus and live virus variants, and
197 elicited anti-spike protein IgG antibodies and T-cell responses within a month after
198 the booster dose.

199 In other booster-dose studies, a third dose of either homologous or
200 heterologous vaccines administered 3-9 months after the initial vaccination elicited
201 robust immunogenicity against SARS-CoV-2 variants [7], [8], [9], [10], [11], [12]. In
202 the COV-BOOST trial, immunogenicity of various types of vaccines given as the third
203 dose was assessed in participants with primary vaccination with either tozinameran
204 or AZD-1222 [12]. While the booster dose of all types of vaccines (mRNA, protein
205 subunit, adenovirus vector, and inactivated virus) amplified immune responses,
206 mRNA vaccines (tozinameran and mRNA-1273) induced more potent
207 immunogenicity than other types of vaccines [12]. Considering that S-268019-b
208 booster is as immunogenic as the tozinameran booster, S-268019-b may elicit more
209 potent humoral immunogenicity than other types of vaccines in the COV-BOOST
210 study, although a direct comparison is not possible between different studies.

211 Although no correlates of protection have been established in COVID-19, the
212 neutralizing antibody titer against SARS-CoV-2 after primary vaccination is highly
213 correlated with clinical efficacy against symptomatic COVID-19 [13]. Humoral
214 immunity in COVID-19 is known to wane over time, especially after 6 months [1], and
215 so does protection against symptomatic COVID-19 [2]. In this study, low baseline
216 neutralizing antibody titers ≥ 6 months after the 2-dose tozinameran vaccination were
217 observed, consistent with previous reports. Meanwhile, studies have reported that a
218 booster dose of tozinameran after 2 doses of tozinameran enhances humoral
219 immunity [7], [12]. Moreover, a report from Israel stated greater efficacy against
220 COVID-19-related hospitalization and death after three versus two tozinameran
221 doses [14]. Since our results show noninferiority of S-268019-b to tozinameran in
222 inducing neutralizing antibodies, it is speculated that S-28019-b may also show
223 clinical efficacy similar to the booster tozinameran, although further investigations to
224 support this are warranted.

225 A previous study showed that the 50% neutralization titer (NT_{50}) against the
226 live Omicron virus after two doses of tozinameran was below the detection limit and
227 61-fold lower compared with the wildtype NT_{50} [15]. However, a booster dose of
228 tozinameran elicited neutralizing antibody titer against Omicron, with NT_{50} only 6-fold
229 lower than that with the wildtype [15]. Moreover, the tozinameran booster dose
230 protected against symptomatic COVID-19 due to Omicron [16]. The current findings
231 also indicate a 4-fold reduction in Omicron neutralizing antibodies versus wildtype;
232 however, S-268019-b and tozinameran are similar with respect to neutralizing

233 antibody levels against Omicron, suggesting that S-28019-b might also show similar
234 clinical efficacy as tozinameran against symptomatic COVID-19 due to Omicron.

235 The T-cell response in COVID-19 is crucial for sustained protection from
236 severe disease progression [17], [18]. Additionally, the T-cell response elicited by
237 COVID-19 infection or prior vaccination is considered cross-reactive against variants,
238 including Omicron [19]. In the current study, we only examined the T-cell response to
239 the original wildtype strain, in which S-268019-b showed a response similar to
240 tozinameran. However, due to the cross-reactive nature of the T-cell response, it is
241 speculated that the T-cell response elicited by S-268019-b may possibly be effective
242 in preventing severe diseases caused by Omicron and other future variants.

243 In this study, both vaccines led to mainly low-grade reactogenicity, with fever,
244 fatigue, myalgia, and injection-site pain being commonly reported, usually within 2
245 days of the booster dose. Compared with tozinameran, S-268019-b led to a lower
246 incidence of solicited TRAEs. Similarly, across all 7 booster vaccines in the
247 COV-BOOST trial, the most frequently solicited AEs reported within 7 days were low-
248 grade fatigue, headache, and local pain [12]. Despite the differences in population
249 and methodologies across different studies, reactogenicity patterns seem largely
250 consistent across studies after the booster dose of either an mRNA [7], [8],
251 adenovirus vector [9], or protein subunit vaccine [10], [11], [12].

252 This is the first clinical trial report of a recombinant spike protein vaccine
253 showing its noninferiority to an mRNA vaccine as a booster dose in Japanese
254 participants. This study has a few limitations. The study (1) included only
255 immunocompetent Japanese adults with no known history of SARS-CoV-2 infection
256 and prior vaccination with only tozinameran, (2) had relatively small sample size, and
257 (3) was not designed for demonstrating clinical efficacy. Also, the interim result had a
258 short follow-up duration. Despite these limitations, a booster dose of the recombinant
259 spike protein vaccine, S-268019-b, elicited robust immunogenicity against SARS-
260 CoV-2, with mostly low-grade reactogenicity.

261

262 **Conclusion**

263 The booster dose of S-268019-b vaccine was noninferior to tozinameran
264 booster as per the findings of GMT and SRR for SARS-CoV-2 neutralizing
265 antibodies, and was well-tolerated in fully vaccinated adult Japanese participants.
266 S-268019-b booster was comparable with tozinameran booster in neutralizing the

267 pseudovirus and live virus variants, Delta and Omicron. Thus, S-268019-b might be
268 a future option for COVID-19 booster vaccine in adults.

269

270 **Funding:** This work was supported by Shionogi & Co., Ltd., and Ministry of Health,
271 Labour and Welfare (MHLW) under its supplementary budget for emergency
272 maintenance associated with the vaccine production system. Preparation of clinical
273 trial materials of S-268019-b was supported by Japan Agency for Medical Research
274 and Development (AMED) under Grant Number JP21nf010626.

275

276 **Acknowledgments:** The authors thank Ms. Kiyomi Kabasawa, Ms Wakana Abe, Ms
277 Harue Otsuka, Ms. Emi Kawabe, Ms. Narumi Iida, and Ms Etsuko Tanaka for
278 supporting clinical trials as clinical research coordinator, and Dr. Kenichi Kamachi
279 and all the staff of Tokyo Shinagawa Hospital for supporting the clinical trials, and
280 Ms. Haruna Hayashi and Mr. Satoshi Kojima (Shionogi & Co., Ltd.) for supporting
281 manuscript development. The authors also thank Dr. Minal Jaggur, PhD, Dr. Vidula
282 Bhole, MD, MHSc, and Mr. Ivan D'Souza, MS, of MedPro Clinical Research for
283 providing medical writing support for this manuscript, which was funded by Shionogi
284 & Co., Ltd.

285

286 **Disclosures/potential conflicts of interests**

287 M. Shinkai, M. Shinoda, T. Sato, and N. Ishii have no conflicts of interest to declare.
288 T. Sonoyama, A. Kamitani, R. Shibata, N. Seki, S. Omoto, K. Igarashi, and M.
289 Ariyasu are employees of Shionogi & Co., Ltd.

290 References

- 291 [1] Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, et al. Waning
292 immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. *N*
293 *Engl J Med* 2021;385:e84. <https://doi.org/10.1056/nejmoa2114583>
- 294 [2] Tartof SY, Slezak JM, Fischer H, Hong V, Ackerson BK, Ranasinghe ON, et
295 al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a
296 large integrated health system in the USA: a retrospective cohort study.
297 *Lancet* (London, England) 2021;398:1407–16. [https://doi.org/10.1016/S0140-](https://doi.org/10.1016/S0140-6736(21)02183-8)
298 [6736\(21\)02183-8](https://doi.org/10.1016/S0140-6736(21)02183-8)
- 299 [3] Garcia-Beltran WF, St. Denis KJ, Hoelzemer A, Lam EC, Nitido AD, Sheehan
300 ML, et al. mRNA-based COVID-19 vaccine boosters induce neutralizing
301 immunity against SARS-CoV-2 Omicron variant. *Cell* 2022;185:457–66.
302 <https://doi.org/10.1016/J.CELL.2021.12.033>
- 303 [4] Gruell H, Vanshylla K, Tober-Lau P, Hillus D, Schommers P, Lehmann C, et
304 al. mRNA booster immunization elicits potent neutralizing serum activity
305 against the SARS-CoV-2 Omicron variant. *Nat Med* 2022:1–4.
306 <https://doi.org/10.1038/s41591-021-01676-0>
- 307 [5] Iwata S, Sonoyama T, Kamitani A, Shibata R, Honma T, Omoto S, et al.
308 Phase 1/2 clinical trial of COVID-19 vaccine in Japanese participants: a report
309 of interim findings. *SSRN Electron J [Internet]* 2022.
310 <https://doi.org/10.2139/ssrn.4008873>
- 311 [6] Office of Vaccines and Blood Products, Pharmaceuticals and Medical Device
312 Agency, Japan. Principles for the evaluation of vaccines against the novel
313 coronavirus SARS-CoV-2 (Appendix 3).
314 <https://www.pmda.go.jp/files/000243339.pdf>; 2021 [accessed 25 February
315 2022].
- 316 [7] Falsey AR, Frenck RW, Walsh EE, Kitchin N, Absalon J, Gurtman A, et al.
317 SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3. *N Engl J Med*
318 2021;385:1627–9. <https://doi.org/10.1056/NEJMc2113468>
- 319 [8] Choi A, Koch M, Wu K, Chu L, Ma L, Hill A, et al. Safety and immunogenicity
320 of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim
321 analysis. *Nat Med* 2021;27:2025–31. [https://doi.org/10.1038/s41591-021-](https://doi.org/10.1038/s41591-021-01527-y)
322 [01527-y](https://doi.org/10.1038/s41591-021-01527-y)
- 323 [9] Flaxman A, Marchevsky NG, Jenkin D, Aboagye J, Aley PK, Angus B, et al.
324 Reactogenicity and immunogenicity after a late second dose or a third dose of
325 ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials
326 (COV001 and COV002). *Lancet* 2021;398:981–90.
327 [https://doi.org/10.1016/S0140-6736\(21\)01699-8](https://doi.org/10.1016/S0140-6736(21)01699-8)
- 328 [10] Mallory R, Formica N, Pfeiffer S, Wilkinson B, Marcheschi A, Albert G, et al.
329 Immunogenicity and safety following a homologous booster dose of a SARS-
330 CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a phase 2
331 randomized placebo-controlled trial. *MedRxiv* 2021:2021.12.23.21267374.
332 <https://doi.org/10.1101/2021.12.23.21267374>

- 333 [11] Cao Y, Hao X, Wang X, Wu Q, Song R, Zhao D, et al. Humoral
334 immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two
335 doses of inactivated vaccine. *Cell Res* 2021;32:107–9.
336 <https://doi.org/10.1038/s41422-021-00596-5>
- 337 [12] Munro APS, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, et al.
338 Safety and immunogenicity of seven COVID-19 vaccines as a third dose
339 (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK
340 (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.
341 *Lancet* 2021;398:2258–76. [https://doi.org/https://doi.org/10.1016/S0140-](https://doi.org/10.1016/S0140-6736(21)02717-3)
342 [6736\(21\)02717-3](https://doi.org/10.1016/S0140-6736(21)02717-3)
- 343 [13] Cromer D, Steain M, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al.
344 Neutralising antibody titres as predictors of protection against SARS-CoV-2
345 variants and the impact of boosting: a meta-analysis. *The Lancet Microbe*
346 2022;3:e52–61. [https://doi.org/10.1016/S2666-5247\(21\)00267-6](https://doi.org/10.1016/S2666-5247(21)00267-6)
- 347 [14] Barda N, Dagan N, Cohen C, Hernán MA, Lipsitch M, Kohane IS, et al.
348 Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for
349 preventing severe outcomes in Israel: an observational study. *Lancet*
350 (London, England) 2021;398:2093–100. [https://doi.org/10.1016/S0140-](https://doi.org/10.1016/S0140-6736(21)02249-2)
351 [6736\(21\)02249-2](https://doi.org/10.1016/S0140-6736(21)02249-2)
- 352 [15] Muik A, Lui BG, Wallisch A-K, Bacher M, Mühl J, Reinholz J, et al.
353 Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited
354 human sera. *Science* 2022;375:678–80.
355 <https://doi.org/10.1126/science.abn7591>
- 356 [16] Accorsi EK, Britton A, Fleming-Dutra KE, Smith ZR, Shang N, Derado G, et al.
357 Association between 3 doses of mRNA COVID-19 vaccine and symptomatic
358 infection caused by the SARS-CoV-2 Omicron and Delta variants. *JAMA*.
359 2022;327(7):639–51. <https://doi.org/10.1001/jama.2022.0470>
- 360 [17] Bilich T, Nelde A, Heitmann JS, Maringer Y, Roerden M, Bauer J, et al. T cell
361 and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term
362 immune responses in COVID-19 convalescent individuals. *Sci Transl Med*
363 2021;13:7517. <https://doi.org/10.1126/scitranslmed.abf7517>
- 364 [18] Moss P. The T cell immune response against SARS-CoV-2. *Nat Immunol*
365 2022;23:186–93. <https://doi.org/10.1038/s41590-021-01122-w>
- 366 [19] Gao Y, Cai C, Grifoni A, Müller TR, Niessl J, Olofsson A, et al. Ancestral
367 SARS-CoV-2-specific T cells cross-recognize the Omicron variant. *Nat Med*
368 2022:1–5. <https://doi.org/10.1038/s41591-022-01700-x>

369 **Figure legends**

370 **Figure 1:** Study design, vaccine regimen, and key assessments

371

372 NT₅₀, 50% neutralization titer.

373

374 **Figure 2:** GMTs in the tozinameran and S-268019-b groups for (A) neutralizing
375 antibodies against live wildtype virus by cytopathic effect, (B) anti-spike protein IgG,
376 (C) NT₅₀ against pseudotyped virus variants, and (D) neutralizing antibodies against
377 live virus variants

378

379 GMT, geometric mean titer; IgG, immunoglobulin G; LLOQ, lower limit of
380 quantification; NT₅₀, 50% neutralization titer.

381 Data are presented as GMTs and 95% CIs. In Figures 2C and 2D, white and grey
382 circles represent individual values for the tozinameran (n=24) and S-268019-b
383 (n=24) groups, respectively, on day 29 for the same sampled cohort. The sampling
384 ensured no significant differences in age and neutralizing antibody titer against live
385 wildtype virus on day 29 compared with the entire cohort.

386 Titer values reported as below the LLOQ were replaced with 0.5 × LLOQ. The LLOQ
387 was 5 for neutralizing antibodies and 100 for anti-spike protein IgG. The 95% CI
388 were constructed using Student's *t* distribution for log-transformed titers.

389

390 **Supplementary Figure 1:** Participant flow

391

392 **Supplementary Figure 2:** Immunologic assays from PBMCs for percent of CD4⁺ T
393 cells positive for IFN- γ , IL-2, IL-4, and IL-5 at baseline and on day 15 in the study
394 groups

395

396 IFN, interferon; IL, interleukin; PBMCs, peripheral blood mononuclear cells.

397 Data are presented as mean and 95% CI. Dark circles represent baseline and light
398 squares represent day 15 values of immune marker expression for individual
399 participants in the study groups (n=29/group). The 95% CI were constructed using
400 the Clopper-Pearson method for proportion data.

401 **Table 1:** Co-primary endpoints (GMT and SRR) with GMTR and SRR difference in
 402 SARS-CoV-2 neutralizing antibody response on day 29, and GMT and SRR at
 403 baseline and on day 15

Outcome (95% CI)	Tozinameran (n=102)			S-268019-b (n=101)		
	Baseline	Day 15 ^a	Day 29 ^a	Baseline	Day 15	Day 29
GMT ^b	6.65 (5.73, 7.72)	139.48 (122.50, 158.82)	109.70 (95.73, 125.70)	5.47 (4.81, 6.21)	127.57 (112.03, 145.28)	124.97 (108.33, 144.18)
Adjusted-GMTR ^c	-	-	-	-	-	1.14 (0.94, 1.39)
SRR ^d	-	99.0 (94.6, 100.0)	100.0 (96.4, 100.0)	-	100.0 (96.4, 100.0)	100.0 (96.4, 100.0)
SRR difference ^d	-	-	-	-	-	0.0 (-5.9, 5.9)

404 GMT, geometric mean titer; GMTR, geometric mean titer ratio; SARS-CoV-2, severe
 405 acute respiratory syndrome coronavirus 2; SRR, seroresponse rate.

406 Criteria for noninferiority confirmed when lower limit of 95% CI >0.67 for GMTR
 407 (S-268019-b/tozinameran) and > -10% for SRR difference (S-268019-b –
 408 tozinameran).

409 ^aOn day 15 and day 29, tozinameran group had 101 participants. ^bThe GMTs with
 410 corresponding 95% CIs were estimated by back transformation from the arithmetic
 411 mean and the 95% CIs based on the Student's *t* distribution of log-transformed titers
 412 to the original scale. ^cThe adjusted-GMTR and its 95% CI were obtained using
 413 analysis of covariance model fitted on the log-transformed titers; the model included
 414 intervention group as the fixed effect as well as age (continuous) and sex as
 415 covariates. ^dThe 95% CI were constructed using the Clopper-Pearson method for
 416 SRR and the Farrington-Manning method for SRR difference.

417 **Table 2:** Incidence of solicited local and systemic treatment-related adverse events (experienced within 7 days after the booster) by
 418 severity in the study groups

	Tozinameran (n=103)				S-268019-b (n=101)			
	Any grade	Grade 1	Grade 2	Grade 3	Any grade	Grade 1	Grade 2	Grade 3
Any systemic solicited TRAEs	82 (79.6)	47 (45.6)	31 (30.1)	4 (3.9)	70 (69.3)	55 (54.5)	14 (13.9)	1 (1.0)
Fatigue	56 (54.4)	33 (32.0)	22 (21.4)	1 (1.0)	43 (42.6)	34 (33.7)	9 (8.9)	-
Fever	61 (59.2)	52 (50.5)	7 (6.8)	2 (1.9)	39 (38.6)	37 (36.6)	1 (1.0)	1 (1.0)
Myalgia	50 (48.5)	43 (41.7)	7 (6.8)	-	40 (39.6)	39 (38.6)	1 (1.0)	-
Headache	43 (41.7)	31 (30.1)	12 (11.7)	-	25 (24.8)	19 (18.8)	6 (5.9)	-
Arthralgia	12 (11.7)	7 (6.8)	5 (4.9)	-	8 (7.9)	6 (5.9)	2 (2.0)	-
Nausea/vomiting	5 (4.9)	5 (4.9)	-	-	5 (5.0)	4 (4.0)	1 (1.0)	-
Diarrhea	6 (5.8)	4 (3.9)	1 (1.0)	1 (1.0)	4 (4.0)	3 (3.0)	1 (1.0)	-
Chills	7 (6.8)	3 (2.9)	4 (3.9)	-	4 (4.0)	2 (2.0)	2 (2.0)	-
Any local solicited TRAEs (at the injection site)	75 (72.8)	70 (68.0)	5 (4.9)	-	68 (67.3)	66 (65.3)	2 (2.0)	-
Pain	75 (72.8)	70 (68.0)	5 (4.9)	-	66 (65.3)	66 (65.3)	-	-
Erythema/redness	10 (9.7)	10 (9.7)	-	-	6 (5.9)	5 (5.0)	1 (1.0)	-
Swelling	1 (1.0)	1 (1.0)	-	-	1 (1.0)	-	1 (1.0)	-

419 TRAEs, treatment-related adverse events.

420 Data are presented as number (%) of participants. No participants reported grade 4 or 5 solicited TRAEs.

Primary endpoints: geometric mean titer and seroresponse rate of neutralizing antibodies on day 29

Secondary endpoints: geometric mean titer, geometric mean fold rise and seroresponse rate of neutralizing antibodies and anti-spike protein IgG antibodies, incidence of adverse events (AEs), treatment-related AEs, serious AEs, solicited AEs, and changes in vital signs, laboratory test values and electrocardiograms

Exploratory endpoints: NT₅₀ against pseudovirus variants, geometric mean titer of neutralizing antibodies against live virus variants, and T-cell cytokine assay

Screening

Evaluation

Follow-up

Healthy adults vaccinated with 2 doses of tozinameran ≥6 months ago (age 20-60 years)

Randomization (1:1)

Location: Japan

Candidate vaccine: 10 µg of S-268019-b in A-910823 (50% v/v)

Active-control: 30 µg of tozinameran in saline

Intramuscular injection of booster (3rd) dose

Day -28

Day 1

Day 15







Day 29

Day 365

Informed consent and eligibility

Study site visit on days 2, 15, and 29 for investigations/examinations

Study site visit on days 69, 183, and 365 for investigations/examinations

A**B****C****D**

Enrollment

Screened (n=206)

Excluded (n=0)

Randomized (n=206)

Excluded (n=2)

Randomization code unclear (n=2)

Allocation





Allocated to tozinameran (n=103)
Received tozinameran (n=103)

Allocated to S-268019-b (n=101)
Received S-268019-b (n=101)

Analyses

Analyzed for safety (n=103)
Analyzed for immunogenicity at baseline (n=102)
Excluded from analysis (n=1)
Confirmed positive anti-SARS-CoV-2 N-protein antibody test at screening (n=1)
Analyzed for immunogenicity on days 15 and 29 (n=101)
Excluded from analysis (n=1)
Confirmed positive anti-SARS-CoV-2 N-protein antibody test after the booster dose (n=1)

Analyzed for safety (n=101)
Analyzed for immunogenicity (n=101)



● Baseline ■ Day 15